These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15782095)

  • 1. A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer.
    Takahashi Y; Mai M; Sawabu N; Nishioka K
    Pancreas; 2005 Apr; 30(3):206-10. PubMed ID: 15782095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tailored-dose chemotherapy using gemcitabine for advanced pancreatic cancer].
    Sumii T; Fujimori N; Nakamura T; Senju T; Horikawa Y; Funakoshi A
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1261-5. PubMed ID: 16969022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [IMRD therapy for patients with metastatic pancreas cancer].
    Yamashita K; Takahashi Y
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():219-22. PubMed ID: 16457254
    [No Abstract]   [Full Text] [Related]  

  • 4. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study.
    Michael A; Hill M; Maraveyas A; Dalgleish A; Lofts F
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):150-3. PubMed ID: 17355112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
    Meyer F; Lueck A; Hribaschek A; Lippert H; Ridwelski K
    Chemotherapy; 2004 Dec; 50(6):289-96. PubMed ID: 15608445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.
    Mohiuddin M; Kudrimoti M; Regine WF; McGrath PC; Hanna N; John W
    Cancer J; 2002; 8(3):255-62. PubMed ID: 12074325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
    Kindler HL; Aklilu M; Nattam S; Vokes EE
    Am J Clin Oncol; 2008 Dec; 31(6):553-6. PubMed ID: 19060586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
    Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.
    Salman HS; Tanaka K; Sparano JA
    Clin Breast Cancer; 2002 Jan; 2(4):299-303. PubMed ID: 11899362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
    Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
    Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
    Brand R; Capadano M; Tempero M
    Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1].
    Fujimoto C; Maruyama Y; Niina Y; Fujimori N; Sumii T; Funakoshi A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1013-6. PubMed ID: 18633236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
    Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
    J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
    Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
    Feliu J; Sáenz JG; Jaráiz AR; Castañón C; Cruz M; Fonseca E; Lomas M; Castro J; Jara C; Casado E; León A; Barón MG
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):419-26. PubMed ID: 16404636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
    Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.